the results show a severely decreased quality of life. This is particularly relevant as physicians' judgment of disease severity has been shown to, albeit inconsistently, correlate with patient-reported scores. Health-related quality of life, rather than clinical severity of disease, was an independent predictor of work productivity. In psoriasis, indirect cost of loss of productivity has been shown to clearly exceed the total direct cost; thus, savings from work productivity might counterbalance the high cost of treatment (biologics in psoriasis, and botulinum toxins in hyperhidrosis). 5 When deciding to use the Skindex-16 instrument, we looked at what have been called weaknesses in DLQI, with its focus on function in daily activities. We found a correlation between the Skindex-16 functioning score and the DLQI score, a finding that supports the statements on the DLQI being more occupied with daily activities while Skindex-16 also measures emotions. The low percentage scores in the physical domain might be explained by the fact that Skindex-16 is not sensitive in that domain, used in hyperhidrosis. The question on perseverance, which is included, is relevant. In conclusion, quality of life in hyperhidrosis is even worse than in other major skin disease. Both instruments performed well overall. Skindex-16 had weaknesses in the physical domain and had its strength in emotions and functioning. DLQI performed strongly in functioning and correlated significantly with Skindex-16 in this domain. As DLQI is weak on emotions, we suggest using the instruments concurrently.